Dapirolizumab pegol

UCB and Biogen announced positive Phase III PHOENYCS GO study results for dapirolizumab pegol, a treatment for moderate-to-severe systemic lupus erythematosus (SLE), showing improvement in disease activity at week 48. The drug, which blocks B cell activation, also reduced disease flares. A second Phase III study, PHOENYCS FLY, will start in 2024.

Biogen and UCB's anti-CD40L candidate, dapirolizumab pegol, met primary endpoint in phase III lupus trial, showing improvement over placebo and standard of care at 48 weeks.

UCB and Biogen's phase 3 trial of dapirolizumab pegol for systemic lupus erythematosus (SLE) was successful, with clinical improvement in primary and secondary endpoints. A second trial, PHOENICS FLY, is expected to start before year-end. If approved, dapirolizumab pegol could offer a new treatment for SLE, a chronic autoimmune disease affecting multiple organ systems.

UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus (SLE), with plans to advance to a second Phase 3 study in 2024. Dapirolizumab pegol, a humanized, Fc-free polyethylene glycol-conjugated antigen-binding fragment, targets the CD40L pathway to reduce B cell activation and autoantibody production, offering a potential new treatment option for SLE.

Biogen and UCB's drug candidate dapirolizumab pegol met primary efficacy endpoint in Phase III PHOENYCS GO study for systemic lupus erythematosus, showing greater improvement of moderate-to-severe disease activity at 48 weeks versus placebo. The treatment also demonstrated clinical improvements in key secondary endpoints. Safety profile was consistent with previous studies. Biogen and UCB plan to initiate another Phase III study, PHOENYCS FLY, this year. Full results to be presented at a medical congress.

UCB and Biogen announce positive Phase 3 PHOENYCS GO study results for dapirolizumab pegol in moderate-to-severe systemic lupus erythematosus (SLE), meeting primary endpoint with greater improvement in disease activity after 48 weeks compared to placebo.

UCB and Biogen's lupus drug met primary endpoint in Phase III PHOENYCS GO trial, showing greater improvement in moderate-to-severe SLE activity. The drug also improved secondary endpoints and maintained a consistent safety profile. UCB's stock rose 2.57% post-announcement. A new Phase III trial, PHOENYCS FLY, will start before year-end.

Biogen and UCB report positive late-stage trial results for experimental lupus drug dapirolizumab pegol, planning a second Phase 3 trial. The drug showed significant improvement over placebo when combined with standard care, with detailed results to be presented at a medical meeting. This could lead to a new therapy for systemic lupus erythematosus (SLE), a challenging autoimmune disease with limited treatment options.

UCB and Biogen report positive Phase 3 PHOENYCS GO study results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus (SLE), meeting primary endpoint of improved disease activity after 48 weeks. The safety profile aligns with previous studies, and a second Phase 3 trial, PHOENYCS FLY, is planned for 2024.